Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

Charles A. (Trey) Leath III, MD
Published: Wednesday, Aug 16, 2017



Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

With recently emerging data, oncologists are better equipped to identify patients who do not need primary cytroreduction. Additionally, Leath says that oncologists now know what to do—and what not to do—at the time of surgery for their patients with ovarian cancer.
 


Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

With recently emerging data, oncologists are better equipped to identify patients who do not need primary cytroreduction. Additionally, Leath says that oncologists now know what to do—and what not to do—at the time of surgery for their patients with ovarian cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x